1887

Abstract

Background and Aims: Type 2 diabetes mellitus (T2DM) is a prevalent disease affecting millions of patients worldwide. The search for new antidiabetic drugs with innovative mechanisms continues. Dapagliflozin is a second agent in a new class of oral antihyperglycemic drugs; the sodium-glucose co-transporter 2 (SGLT2) inhibitors. Materials and Method: Aim: To evaluate the efficacy of new oral antihyperglycemic drug Dapagliflozin in the treatment of type 2 DM as monotherapy or combination with other hypoglycemic agents. All patients treated with Dapagliflozin in HGH since its introduction as nonformulary medication on 1st April 2013 until 30th April 2015 were included. Data regarding prescribed drugs were obtained from the pharmacy computerized system. Demographic information and laboratory results of patients were obtained from the patient»s electronic system (CERNER). Results: 81 patients were identified to receive Dapagliflazone during the study period, 71 % of them were males, 100 % were Qataries with mean age 57 ± 9 and mean A1c baseline 9 ± 1.4Dapagliflozin as add-on therapy was found to decrease A1c significantly after 6 months by − 0.8 (P = 0.006) and after 12 months by − 1.5 (P = 0.062) The fasting blood was significantly reduced at 6 months and 9 months (P = 0.001, P = 0.03 respectively) There was no significant association between different coadministered antidiabetic medication and reduction in A1c or FBG Conclusion: Dapagliflozin significantly reduced HbA1c level of type 2 diabetic patients in combination of other OHA or insulin within 6 to 12 months of treatment References: 1. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85(5), 513–519 (2009) 2. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35, 1473–1478 (2012).

Loading

Article metrics loading...

/content/papers/10.5339/qfarc.2018.HBPD239
2018-03-15
2019-11-14
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/papers/10.5339/qfarc.2018.HBPD239
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error